Coronado Industries Predicts 2005 to Be Banner Year; Focus is on Increasing Sales and FDA Approval.

FOUNTAIN HILLS, Ariz. -- Coronado Industries Inc. (OTC BB: CDIK), the manufacturers of unique proprietary pneumatic devices for the non-invasive treatment of glaucoma, predicts 2005 to be a banner year.

Company President Gary Smith said, "We've finally turned the corner with this company. Everything is in place to move forward. We have secured our 2A approval for sales, we've had two articles accepted for publication, the study currently under way in Italy is showing positive results on patients and marketing is under way in Europe. Our credibility with PNT has never been higher than it is right now."

Taking advantage of this situation is Dr. Francesco Aspes, Coronado's head of Europe, who at the present time is negotiating sales agreements for distribution rights in at least 10 additional countries throughout the European Union.

CEO of Coronado G. Richard Smith stated, "Interest is high and we are moving rapidly. We sold and delivered 22 PNT units in the last 30 days -- we have shipped 85 units under our European agreements to date and we have built-in monthly orders for the next five years, not counting the new agreements being negotiated."

What does this mean to our company and our stockholders? Smith went on to say, "Each month as we sell more units, they increase our total sales -- but, more importantly, they increase our controller base upon which our disposable rings are used in the treatment of patients. Though I cannot comment on the specific prices of rings and units at this time, I can tell you that each unit actively used in the field should provide Coronado with approximately $5,000-$7,000 annually in ring sales. The important point to remember is that each month, year after year, the controller base will continue to grow and therefore our ring sales will compound annually. Because of our patent protection on both the product and on the medical procedure itself -- this forecast should remain fairly undisturbed by any competitors in the marketplace. There is no question that it has been a struggle to get to this point; however, it looks like we are finally in the right place at the right time."

Dr. John Sharkey, Coronado's director of operations, is directing his focus on the U.S. market and securing our FDA approval. To that end, discussions are under way with interested companies that would be willing to complete our FDA requirements for exclusive rights to the highly profitable U.S. market. Steps are being taken to provide Coronado with an alternative path to gain FDA approval in case of any undue delay with the signing of an agreement with one of these interested parties.

Dr. Sharkey stated, "No amount of money, time or effort would be too much to spend in completion of our FDA approval process because once achieved, current sales estimates for the U.S. market exceed $100 million per year."

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.